FDA approved the Ventana ALK CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with the Novartis drug Zykadia (ceritinib).
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
